leaf.png
leaf.png
leaf.png

Accelerated Clinical Licensing Program: CTCL Sezary is a rare disease with a high mortality rate and unmet needs. It has an accelerated licensing program in the U.K. which will enable the Company to efficiently bring its treatments to market.

 

Experienced Management Team: The Company possesses expertise across a wide variety of industries, ranging from agriculture to real estate. The management team also includes industry professionals that specialize in research as well as professionals that specialize in business. This enables the Company to be well positioned for all stages of the process, from drug development to eventual sales and distribution.

 

Product Offering Validation: The products have a scientific foundation and have received/are in the process of receiving R&D validation. MedC has a unique drug development platform that was developed by Professor Hinanit Koltai at the Israeli National Medical Cannabis Lab at ARO Volcani. This methodology allows us to screen various combinations of cannabinoids against a variety of medical indications. The Company’s approach to treating patient indication with unmet needs allows the Company to operate in a niche market that is optimal for generating revenues in this industry. Novel treatments for CTCL Sezary and CTCL MF have already been peer-reviewed on Oncotarget (March2020) and validated at Rabin Medical Center laboratories with a 95% reduction in Malignant T-Cells in Sezary and 90% reduction in Malignant T-Cells in MF.

 

Versatility of Products: The Company’s drug development program, based on a sound data-led methodology, enables the Company to pursue drug development for a variety of acute dermatology and skin oncology indications. Validation of the Company’s first drug will demonstrate the effectiveness of this methodology and MedC’s potential in pursuing additional indications. These include but are not limited to Actinic Keratosis, BCC and SCC (more common forms of skin cancer).

 

Global Presence: The Company currently spans across three continents, with offices in Israel, Canada, and the U.K. After the official validation of its products, the Company plans to roll-out its products globally. With a strong global presence, the Company is well-positioned to capture a wide variety of end-markets and increase its revenue.

leaf.png
leaf.png